Insys Therapeutics Inc (INSY)

13.22
0.50 3.64
NASDAQ : Health Care
Prev Close 13.72
Open 13.98
Day Low/High 13.00 / 14.00
52 Wk Low/High 11.45 / 46.17
Volume 900.56K
Avg Volume 649.00K
Exchange NASDAQ
Shares Outstanding 72.13M
Market Cap 947.73M
EPS 0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Opioid Marketing Under Bipartisan Investigation

Opioid Marketing Under Bipartisan Investigation

Individual state investigations of opioid marketing practices has lead to a multistate investigation of the prescription painkiller industry.

Depomed, Insys Shares Down After FDA Decision on Endo's Opana ER

Depomed, Insys Shares Down After FDA Decision on Endo's Opana ER

The FDA requested Endo to remove its opioid pain medication from the market, expressing concern that the "benefits of the drug may no longer outweigh its risks."

Launch of Cannabis ETF May Not Be Best Option for Investors

Launch of Cannabis ETF May Not Be Best Option for Investors

Although a cannabis ETF launched in April, investors are still likely to find more value in buying individual stocks in the sector, according to traders.

Biotech Movers: Array Shares Rise on Bristol-Myers Collaboration

Biotech Movers: Array Shares Rise on Bristol-Myers Collaboration

Array BioPharma, Advaxis, Merrimack Pharmaceuticals and Insys Therapeutics were among the biotech stock movers in premarket trading on Tuesday.

INSY Crosses Above Average Analyst Target

In recent trading, shares of Insys Therapeutics Inc have crossed above the average analyst 12-month target price of $14.00, changing hands for $14.21/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Insys Therapeutics, Inc. Announces FDA Final Product Label For Syndros

Launch Planned for August 2017

INSY: Insiders vs. Shorts

The most recent short interest data was recently released for the 04/28/2017 settlement date, and Insys Therapeutics Inc is one of the most shorted stocks of the Russell 3000, based on 20.51 "days to cover" versus the median component at 4.80. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Raytheon, Celgene, Orbital ATK, CenturyLink: 'Mad Money' Lightning Round

Raytheon, Celgene, Orbital ATK, CenturyLink: 'Mad Money' Lightning Round

Jim Cramer is bullish on Raytheon, Celgene, and Orbital ATK; he's bearish on CenturyLink and Pennsylvania Real Estate Investments.

It's Hard to Find Winners and Stick With Them: Cramer's 'Mad Money' Recap (Tuesday 5/16/17):

It's Hard to Find Winners and Stick With Them: Cramer's 'Mad Money' Recap (Tuesday 5/16/17):

Jim Cramer says Home Depot, AMD and Alphabet are three examples of winners that have been so hard to stay in that he think you can still buy.

Analysts' Actions -- Allergan, Coach, General Dynamics, Occidental and More

Analysts' Actions -- Allergan, Coach, General Dynamics, Occidental and More

Here are Wednesday's top research calls, including downgrades for Allergan and General Dynamics, and upgrades for Coach and Occidental Petroleum.

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed In U.S. District Court To Recover Losses Suffered By Investors In INSYS Therapeutics, Inc.

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired shares of INSYS Therapeutics, Inc.

May 16 Deadline Alert: Law Offices Of Howard G. Smith Reminds Insys Therapeutics, Inc. Investors Of Upcoming Lead Plaintiff Deadline And Encourages Investors To Contact The Firm

Law Offices of Howard G. Smith reminds investors of the upcoming  May 16, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of a class of investors who purchased or otherwise...

5 Earnings Short-Squeeze Plays: Snap, NVIDIA & More

5 Earnings Short-Squeeze Plays: Snap, NVIDIA & More

These heavily shorted stocks could squeeze the short-sellers if they report bullish earnings this week.

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Has Filed In U.S. District Court To Recover Losses Suffered By Investors In INSYS Therapeutics, Inc.

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired shares of INSYS Therapeutics, Inc.

Biotech Movers: Synergy, Biogen, Insys

Biotech Movers: Synergy, Biogen, Insys

Synergy Pharmaceuticals, Biogen and Insys Therapeutics were among the biotech stock movers in premarket trading on Thursday.

Biotech Movers Trading Positive Ahead of Market's Open

Biotech Movers Trading Positive Ahead of Market's Open

Intellia Therapeutics led the movers.

DepoMed, Opioid Makers Fall After Trump's FDA Pick Says America's Drug Addiction Is Out of Control

DepoMed, Opioid Makers Fall After Trump's FDA Pick Says America's Drug Addiction Is Out of Control

Washington needs to do more, Gottlieb says at his confirmation hearing.

Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of Insys Therapeutics, Inc. Investors And Encourages Investors To Contact The Firm

Glancy Prongay & Murray LLP ("GPM") announces that a class action lawsuit has been filed on behalf of investors who purchased Insys Therapeutics, Inc.

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In INSYS Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...